{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:42:16Z","timestamp":1792788136370,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Erlangen","id":[{"id":"https:\/\/ror.org\/0030f2a11","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate comparative effectiveness of methotrexate (MTX), calcineurin inhibitors (CNI), Janus kinase inhibitors (JAKi), and biologics for the first-line therapies in adult-onset Still\u2019s disease (AOSD) in real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two AOSD cohorts were retrospectively analysed. First, effectiveness of first-line biological versus non-biologic modulator was validated using overlap weighting of propensity scores in the Shanghai AOSD cohort. To compare AOSD treatment strategies (MTX, CNI, JAKi, biologics), we pooled data from the Shanghai and Erlangen cohorts, emulated a target trial, and applied doubly robust weighted regression to adjust for demographic and clinical confounders. The primary outcome was sustained event-free remission over 12 and 72 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      124 AOSD patients were analyzed, 96 from the Shanghai and 28 from Erlangen cohort. In overlap-weighted analyses of Shanghai cohort, biologic was associated with higher sustained event-free remission and event-free state than non-biologic immune modulators (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0065 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0096). In the pooled analysis, biologics were linked to higher likelihood of event-free state and sustained event-free remission at weeks 12 and 72 (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Pairwise comparisons confirmed the advantage of biologics over CNI (sustained event-free remission at week 72 OR 0.11,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), with significant benefits over MTX (OR 0.12,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) and JAKi (OR 0.14,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008) emerging at week 72 for sustained event-free remission, and more frequent glucocorticoid discontinuation than MTX and CNI (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>First-line biological treatment is associated with improved sustained event-free remission compared to non-biologic treatments, such as MTX, CNI and JAKi and associated with more favorable long-term outcomes in AOSD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-026-03861-3","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:06:16Z","timestamp":1784549176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of first-line biologic immunomodulation compared with non-biologic therapies in adult-onset Still\u2019s disease: a two-center cohort study"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0066-9153","authenticated-orcid":false,"given":"Ruru","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"10","key":"3861_CR1","doi-asserted-by":"publisher","first-page":"103880","DOI":"10.1016\/j.autrev.2025.103880","volume":"24","author":"P Ruscitti","year":"2025","unstructured":"Ruscitti P, Cantarini L, Ciccia F, Conti F, Dagna L, Iannone F, et al. Managing the clinical heterogeneity of patients with Still\u2019s disease, from early diagnosis to timely treatment. Autoimmun Rev. 2025;24(10):103880.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"3861_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41584-023-01065-6","volume":"20","author":"P Ruscitti","year":"2024","unstructured":"Ruscitti P, Cantarini L, Nigrovic PA, McGonagle D, Giacomelli R. Recent advances and evolving concepts in Still\u2019s disease. Nat Rev Rheumatol. 2024;20(2):116\u201332.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"3861_CR3","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2665-9913(25)00023-2","volume":"7","author":"A Kernder","year":"2025","unstructured":"Kernder A, Filla T, Friedrich R, Blank N, Ernst D, Henes J, et al. First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still\u2019s disease: a multicentre, retrospective, propensity weighted cohort study. Lancet Rheumatol. 2025;7(6):e415\u201323.","journal-title":"Lancet Rheumatol"},{"issue":"14","key":"3861_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1080\/14656566.2022.2126764","volume":"23","author":"I Di Cola","year":"2022","unstructured":"Di Cola I, Cipriani P, Ruscitti P. Perspectives on the use of non-biological pharmacotherapy for adult-onset Still\u2019s disease. Expert Opin Pharmacother. 2022;23(14):1577\u201387.","journal-title":"Expert Opin Pharmacother"},{"key":"3861_CR5","doi-asserted-by":"publisher","first-page":"152244","DOI":"10.1016\/j.semarthrit.2023.152244","volume":"62","author":"P Ruscitti","year":"2023","unstructured":"Ruscitti P, Sota J, Vitale A, Lopalco G, Iannone F, Morrone M, et al. The administration of methotrexate in patients with Still\u2019s disease, real-life findings from AIDA Network Still Disease Registry. Semin Arthritis Rheum. 2023;62:152244.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"3861_CR6","first-page":"201","volume":"54","author":"M Kuinose","year":"2000","unstructured":"Kuinose M, Iwagaki H, Morimoto Y, Kohka H, Kobashi K, Sadamori H, et al. Calcineurin antagonists inhibit interferon-gamma production by downregulation of interleukin-18 in human mixed lymphocyte reactions. Acta Med Okayama. 2000;54(5):201\u20139.","journal-title":"Acta Med Okayama"},{"issue":"Suppl 127","key":"3861_CR7","first-page":"11","volume":"38","author":"H Nakamura","year":"2020","unstructured":"Nakamura H, Fujieda Y, Tarumi M, Kitakawa H, Hisada R, Nakagawa I, et al. Calcineurin inhibitors for adult-onset Still\u2019s disease: a multicentre retrospective cohort study. Clin Exp Rheumatol. 2020;38(Suppl 127):11\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"3861_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"3861_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea Y, Nakayamada JJ. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133\u201345.","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"3861_CR10","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1136\/ard-2024-225851","volume":"83","author":"B Fautrel","year":"2024","unstructured":"Fautrel B, Mitrovic S, De Matteis A, Bindoli S, Ant\u00f3n J, Belot A, et al. EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Ann Rheum Dis. 2024;83(12):1614\u201327.","journal-title":"Ann Rheum Dis"},{"key":"3861_CR11","doi-asserted-by":"publisher","first-page":"101632","DOI":"10.1016\/j.smim.2022.101632","volume":"58","author":"P Ruscitti","year":"2021","unstructured":"Ruscitti P, Berardicurti O, Giacomelli R, Cipriani P. The clinical heterogeneity of adult onset Still\u2019s disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients. Semin Immunol. 2021;58:101632.","journal-title":"Semin Immunol"},{"issue":"4","key":"3861_CR12","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1093\/rheumatology\/keac439","volume":"62","author":"R Guo","year":"2023","unstructured":"Guo R, Liu X, Li Y, Meng X, Li R, Chen X, et al. AOSD endotypes based on immune cell profiles: patient stratification with hierarchical clustering analysis. Rheumatology (Oxford). 2023;62(4):1636\u201344.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"3861_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","volume":"70","author":"J Pouchot","year":"1991","unstructured":"Pouchot J, Sampalis JS, Beaudet F, Carette S, D\u00e9cary F, Salusinsky-Sternbach M, et al. Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients. Med (Baltim). 1991;70(2):118\u201336.","journal-title":"Med (Baltim)"},{"issue":"3","key":"3861_CR14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S, Horne A, Bovis F, Pistorio A, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;68(3):566\u201376.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3861_CR15","first-page":"250","volume":"188","author":"F Li","year":"2019","unstructured":"Li F, Thomas LE, Li F. Addressing Extreme Propensity Scores via the Overlap Weights. Am J Epidemiol. 2019;188(1):250\u20137.","journal-title":"Am J Epidemiol"},{"issue":"23","key":"3861_CR16","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","volume":"323","author":"LE Thomas","year":"2020","unstructured":"Thomas LE, Li F, Pencina MJ. Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial. JAMA. 2020;323(23):2417\u20138.","journal-title":"JAMA"},{"issue":"3","key":"3861_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40265-024-01993-x","volume":"84","author":"S Bindoli","year":"2024","unstructured":"Bindoli S, Baggio C, Doria A, Sfriso P. Adult-Onset Still\u2019s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options. Drugs. 2024;84(3):257\u201374.","journal-title":"Drugs"},{"issue":"3","key":"3861_CR18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10067-024-06905-8","volume":"43","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Kataoka Y, Otani T, Taniguchi Y, Ikeda K, Tamura N, et al. Optimal time of starting tocilizumab in acute phase of adult-onset Still\u2019s disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature. Clin Rheumatol. 2024;43(3):1245\u201351.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3861_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11739-024-03766-6","volume":"20","author":"B Kilic","year":"2025","unstructured":"Kilic B, Parlar K, Karup S, Ozturk A, Karaahmetli K, Ugurlu S. Anakinra in the management of adult-onset still\u2019s disease: a single-center experience. Intern Emerg Med. 2025;20(1):131\u20138.","journal-title":"Intern Emerg Med"},{"key":"3861_CR20","doi-asserted-by":"publisher","first-page":"1256243","DOI":"10.3389\/fmed.2023.1256243","volume":"10","author":"A Vitale","year":"2023","unstructured":"Vitale A, Caggiano V, Sfikakis PP, Dagna L, Lopalco G, Ragab G, et al. Efficacy of canakinumab in patients with Still\u2019s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still\u2019s Disease. Front Med (Lausanne). 2023;10:1256243.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"3861_CR21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/ard.2006.066381","volume":"66","author":"GD Kalliolias","year":"2007","unstructured":"Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN. Anakinra treatment in patients with adult-onset Still\u2019s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66(6):842\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3861_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"3861_CR23","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406.","journal-title":"N Engl J Med"},{"issue":"25","key":"3861_CR24","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395.","journal-title":"N Engl J Med"},{"issue":"11","key":"3861_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/1744666X.2017.1375853","volume":"13","author":"P Ruscitti","year":"2017","unstructured":"Ruscitti P, Ursini F, Cipriani P, De Sarro G, Giacomelli R. Biologic drugs in adult onset Still\u2019s disease: a systematic review and meta-analysis of observational studies. Expert Rev Clin Immunol. 2017;13(11):1089\u201397.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"3861_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","volume":"82","author":"F De Benedetti","year":"2023","unstructured":"De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82(6):857\u201365.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3861_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545\u201355.","journal-title":"Arthritis Rheum"},{"key":"3861_CR28","doi-asserted-by":"publisher","first-page":"112451","DOI":"10.1016\/j.intimp.2024.112451","volume":"137","author":"J Liao","year":"2024","unstructured":"Liao J, Tang Q, Xie X, Zhou B, Li F, Li S. The efficacy and safety of JAK inhibitors in patients with adult-onset still\u2019s disease: A meta-analysis and systematic review. Int Immunopharmacol. 2024;137:112451.","journal-title":"Int Immunopharmacol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03861-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03861-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03861-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:57:05Z","timestamp":1792061825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03861-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3861"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03861-3","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from all participants according to the recommendations of the Declaration of Helsinki. This study was approved by the institutional review board of Renji Hospital (approval number 2016083).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"181"}}